CN1485034A - Rifaximin suspension mix granule formulation - Google Patents
Rifaximin suspension mix granule formulation Download PDFInfo
- Publication number
- CN1485034A CN1485034A CNA021310351A CN02131035A CN1485034A CN 1485034 A CN1485034 A CN 1485034A CN A021310351 A CNA021310351 A CN A021310351A CN 02131035 A CN02131035 A CN 02131035A CN 1485034 A CN1485034 A CN 1485034A
- Authority
- CN
- China
- Prior art keywords
- rifaximin
- granule formulation
- agent
- suspension mix
- mix granule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
A dried rifaximin suspensoid pelletized granule, which is prepared by mixing rifaximin as the active component and medicinal auxiliary materials at the weight ratio of 1:5-35. The medicinal auxiliary materials mainly comprise the suspending agent and the flocculating agent at the weight ratio of 1:0.05-2. The suspending agent comprises two or three of microcrystal cellulose, methylcellulose, sodium methylol cellulose, hydroxypropyl methylcellulose, sodium alginate, gum arabic and pectine. The flocculating agent is one of citrate, tartrate, phosphate and aluminum chloride. Other auxiliary materials contain cane sugar, starch, food sweetening agent, preservative and flavoring and so on.
Description
Technical field
The present invention relates to medicine field, particularly relate to a kind of Rifaximin suspension mix granule formulation for the treatment of intestinal tract disease.
Background technology
Rifaximin is a widely used new antibiotic in the Ryfamycin derivative, and it can be used for treating the acute and chronic intestinal that is caused by gram positive bacteria and gram negative bacteria and infects, and can be used as the ancillary drug of hyperammonemia treatment.This medicine antibacterial spectrum is wide, and aerobe in the gastrointestinal tract or anaerobe are all had antibacterial action.Its maximum characteristics are that not inhaled intestinal absorption not purified by gastric juice yet, be that this product does not almost have system's absorption, the patient takes the back and detects less than drug level in its urine and tissue, and just drain with its prototype through large intestine, thereby its toxic and side effects is extremely low, especially suitable treatment adult and children's diarrhae.Chinese patent application numbers 98106920 discloses a kind of purposes of rifaximin, it is a diarrhoea of utilizing rifaximin to treat to suffer from the immunosuppressive disease philtrum of severe form to cause because of cryptosporidiosis, because the indication of this invention is more single, thereby the field of using is narrower; And the rifaximin that uses clinically at present mostly is tablet, is difficult for swallowing, and especially is unsuitable for being used for the treatment of swallowing old age or the child's intestinal infection patient who has difficulties.
Summary of the invention
In order to address the above problem, the object of the present invention is to provide a kind of taking convenience, drug effect is complete, bioavailability is high, wide accommodation and the good Rifaximin suspension mix granule formulation of mouthfeel.
In order to achieve the above object, Rifaximin suspension mix granule formulation provided by the invention is mainly by mixing with 1: 5～35 weight ratio as the rifaximin of active component and pharmaceutic adjuvant, pharmaceutic adjuvant mainly comprises with blended suspending agent of 1: 0.05～2 weight ratio and flocculating agent, suspending agent is two kinds to three kinds in microcrystalline Cellulose, methylcellulose, sodium carboxymethyl cellulose, hydroxypropyl emthylcellulose, sodium alginate, arabic gum and the pectin, and flocculating agent is any one in citrate, tartrate, phosphate and the aluminum chloride; Other adjuvant comprises sucrose, starch, sweeting agent, antiseptic and flavoring agent etc.
It is big that Rifaximin suspension mix granule formulation provided by the invention has the convenience of swallowing, medicine and gastrointestinal contact area than solid oral dosage forms such as single tablets, thereby effect and absorbing fully, thereby can improve plurality of advantages such as bioavailability of drugs, available water was made into suspension before particularly it was taken, and the sweeting agent that adds etc. also can improve the abnormal flavour of common drug, thereby very is suitable for old age and child patient is taken.
The specific embodiment
In order to increase the flotation property of suspension mix granule formulation of the present invention, the holdup time of prolong drug in gastrointestinal tract, soak time is prolonged, thereby reduce dosage and alleviate the toxic and side effects that bring to the patient back of taking medicine, improve therapeutic effect, having added some in medicine increases solution viscosity, reduces the material of drug microparticles sedimentation velocity as suspending agent; In addition, the flocculating agent of adding can make electrolyte concentration increase in the solution, the appropriate change solution potential, and can make drug microparticles be difficult for coalescent in bulk and good dispersion.
Embodiment 1
With 1000 bags of Rifaximin suspension mix granule formulations is benchmark; at first 200g rifaximin, 65g sodium carboxymethyl cellulose, 30g microcrystalline Cellulose, 65g pectin, 90g sodium citrate and 2250g sucrose powder were placed the powdery material mixing machine uniform mixing 30 minutes; then this mixture being put into the compression comminutor carries out making orange-yellow granular formulations after the dry type compression; carry out packing at last, every bag contains rifaximin 200mg.
Embodiment 2
With 1000 bags of Rifaximin suspension mix granule formulations is benchmark; at first 200g rifaximin, 85g sodium carboxymethyl cellulose, 85g pectin, 110g sodium citrate, 500g sucrose powder, 500g corn starch, 300g were placed the powdery material mixing machine uniform mixing 30 minutes for sugared sorbitol, 30g as the natural fragrant citrus and the 50g Herba Gynurae bicoloris of flavoring agent; then this mixture being put into the compression comminutor carries out making orange-yellow granular formulations after the dry type compression; carry out packing at last, every bag contains rifaximin 200mg.
Claims (4)
1, a kind of Rifaximin suspension mix granule formulation, it is characterized in that: described Rifaximin suspension mix granule formulation is mainly by mixing with 1: 5～35 weight ratio as the rifaximin of active component and pharmaceutic adjuvant, pharmaceutic adjuvant mainly comprises with blended suspending agent of 1: 0.05～2 weight ratio and flocculating agent, suspending agent is a microcrystalline Cellulose, methylcellulose, sodium carboxymethyl cellulose, hydroxypropyl emthylcellulose, sodium alginate, in arabic gum and the pectin two kinds to three kinds, flocculating agent is a citrate, tartrate, in phosphate and the aluminum chloride any one.
2, Rifaximin suspension mix granule formulation according to claim 1 is characterized in that: the mixture of described suspending agent preferably carboxymethyl cellulose sodium and microcrystalline Cellulose.
3, Rifaximin suspension mix granule formulation according to claim 1 is characterized in that: described flocculating agent preferably citric acid salt.
4, Rifaximin suspension mix granule formulation according to claim 1 is characterized in that: described Rifaximin suspension mix granule formulation also can comprise other adjuvants such as sucrose, starch, sweeting agent, antiseptic and flavoring agent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA021310351A CN1485034A (en) | 2002-09-26 | 2002-09-26 | Rifaximin suspension mix granule formulation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA021310351A CN1485034A (en) | 2002-09-26 | 2002-09-26 | Rifaximin suspension mix granule formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1485034A true CN1485034A (en) | 2004-03-31 |
Family
ID=34144750
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA021310351A Pending CN1485034A (en) | 2002-09-26 | 2002-09-26 | Rifaximin suspension mix granule formulation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1485034A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101836959A (en) * | 2010-05-20 | 2010-09-22 | 山东达因海洋生物制药股份有限公司 | Method for preparing almost bitterless rifaximin dry suspension |
| WO2011110930A2 (en) | 2010-03-10 | 2011-09-15 | Lupin Limited | Rifaximin ready-to-use suspension |
| CN102218078A (en) * | 2011-04-19 | 2011-10-19 | 南京威泰珐玛兽药研究所有限公司 | Rifaximin suspension containing montmorillonite and preparation method thereof |
| CN110623929A (en) * | 2019-09-17 | 2019-12-31 | 南京臣功制药股份有限公司 | Rifaximin dry suspension and preparation method thereof |
-
2002
- 2002-09-26 CN CNA021310351A patent/CN1485034A/en active Pending
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011110930A2 (en) | 2010-03-10 | 2011-09-15 | Lupin Limited | Rifaximin ready-to-use suspension |
| US9211258B2 (en) | 2010-03-10 | 2015-12-15 | Lupin Limited | Rifaximin ready-to-use suspension |
| CN101836959A (en) * | 2010-05-20 | 2010-09-22 | 山东达因海洋生物制药股份有限公司 | Method for preparing almost bitterless rifaximin dry suspension |
| CN102218078A (en) * | 2011-04-19 | 2011-10-19 | 南京威泰珐玛兽药研究所有限公司 | Rifaximin suspension containing montmorillonite and preparation method thereof |
| CN102218078B (en) * | 2011-04-19 | 2012-10-10 | 南京威泰珐玛兽药研究所有限公司 | Rifaximin suspension containing montmorillonite and preparation method thereof |
| CN110623929A (en) * | 2019-09-17 | 2019-12-31 | 南京臣功制药股份有限公司 | Rifaximin dry suspension and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2242413T3 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING LIPASA INHIBITORS. | |
| KR100255887B1 (en) | Laxative composition containing lactic acid bacterium | |
| JPH08503482A (en) | Cimetidine granules coated with partially hydrogenated vegetable oil | |
| CN101352449B (en) | Vitamin orally disintegrating tablet and preparation method thereof | |
| EP1105123A1 (en) | Pharmaceutical compositions containing lipase inhibitors and chitosan | |
| US20080044493A1 (en) | Agent For Ameliorating The Maximum Passage Time Through Digestive Tract, Agent For Ameliorating Passage Time Through Digestive Tract And Preventive For Colon Cancer | |
| WO1999001149A1 (en) | Health supplement | |
| KR100278875B1 (en) | Silium Beverage Mix Composition Containing Granulated Base | |
| CN101433332B (en) | Food replenisher for improving function of intestinal canal, moistening intestines and relaxing the bowels, and preparation method thereof | |
| JP2006335648A (en) | Method for producing granular oral composition with oligosaccharide solution | |
| WO2005084703A1 (en) | Sustained-release composition for oral cavity | |
| BRPI0821454B1 (en) | pharmaceutical formulation, mixture of glycogen, alginate and alkaline earth metal salts, processes for the production of a slow release excipient, and a pharmaceutical form | |
| ES2501966T3 (en) | New pharmaceutical composition for use as a laxative | |
| WO2002026213A1 (en) | Pharmaceutical composition containing psyllium fiber and a lipase inhibitor | |
| CN1485034A (en) | Rifaximin suspension mix granule formulation | |
| CN102772383A (en) | Azithromycin composition freeze-dried orally disintegrating tablet and preparation method thereof | |
| JPH08504593A (en) | Plantain drink mix composition | |
| CN105832993B (en) | Composition with throat clearing function and preparation method and application thereof | |
| CN106063788B (en) | Application of phillyrin, phillyrin derivatives, and phillyrin-phillygenin composition in preparation of drugs for relieving or/and treating emesis | |
| JPH05238945A (en) | Intestinal environment-improving agent | |
| CN109219358A (en) | For reducing the edible composition of nocuousness/toxicant digestibility or absorptivity | |
| CA2523339A1 (en) | Agent for preventing and healing constipation | |
| PL229133B1 (en) | Bioavailable composition of rhamnose-containing flavonoids and its application | |
| CN101589806A (en) | A kind of solid low-energy food that is rich in dietary fiber and polyethylene glycol and preparation method thereof | |
| WO1995020954A1 (en) | Tablets containing thyroid hormones |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |